Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2009

View Archived Issues

NK3 receptor antagonists claimed by Roche

GlaxoSmithKline presents novel IGF-1R inhibitors for cancer treatment

Novel nAChR receptor modulators claimed by NeuroSearch

Schering-Plough presents novel gamma-secretase modulators

Novel LXRbeta ligands discovered by Roche

GSK-962040: A novel small-molecule motilin receptor agonist for gastric stasis

Paladin files new drug submission for Trelstar 6-month formulation

FDA approves Dara's IND to begin phase I studies in humans of DB-959 for type 2 diabetes

IMUC and Formatech sign agreement for development of optimal formulation of ICT-121

Advaxis submits ADXS-11-001 to FDA for orphan drug designation

Celator enrolls first patient in phase II CPX-351 trial in acute myeloid leukemia

Preclinical data on anti-HCV drug PF-00868554 published

Custirsen combined with docetaxel shows increased efficacy and safety in prostate cancer

Fosrenol launched in Japan for hyperphosphatemia

NVC-422 shows antifungal activity in animal model of dermatophytosis

WAY-207024 is a novel orally active antagonist of GnRH receptor

Icagen initiates senicapoc study in patients with exercise-induced asthma

Medicure cleared to commence phase II Avastrem trial for tardive dyskinesia

Merrion commences dosing of Orazol in U.S. clinical study

StemEx receives orphan medicinal product designation in Europe

TrialNet centers begin Diamyd vaccine studies for recent-onset type 1 diabetes

Targacept to discontinue development of TC-6499 for neuropathic pain

Nanotherapeutics presents update on clinical development programs

Dynavax and AstraZeneca extend research collaboration in asthma and COPD

Taiho and Toray initiate codevelopment of beta3-adrenoceptor agonist TRK-380/TAC-301

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...